| INTRODUCTION
The D antigen is one of the most important blood group antigens because of its implication in transfusion practice and fetal mater- 
| MATERIALS AND METHODS

| Samples
A total of 21 353 samples from pregnant women was submitted to our laboratory for D typing during 2-year period and samples showed D typing discrepancies were further analyzed. All patients had a high degree of admixture between descendants of Europeans, Africans and Native-Americans in their ethnic background. The study was conducted in accordance with our institutional ethical review. 
| Serologic analysis
| RESULTS
A total of 104 pregnant women samples with discrepant results or weak reactivity with two monoclonal anti-D reagents in routine diagnostics were tested by hemagglutination with currently used MoAbs in Brazil and by molecular analyses. 
| Molecular analyses
| Serologic D typing
The reactivity with the monoclonal anti-D reagents showed a generally consistent pattern among the variant RHD alleles that occurred more than once, which means that all weak D types samples showed a similar serological profile. 
| DISCUSSION
Appropriate classification of RhD phenotypes is ethically recommended for correct indication of RhIG in pregnant women. However, the serologic distinction between RhD-negative and RhD-positive phenotypes is a difficult task in the case of D variants due to the variations in serologic testing. 17 In the last years, RhD typing practice and recommendation of RhIG for pregnant women is changing with the introduction of molecular testing in the routine and a recent publication from a Work Group in the United States emphasizes that it is time to begin to phase in selective genotyping to promote more personalized medicine. 13 We report a serologic and molecular study of D variants in pregnant women with a multiethnic background who were identified be- be up to 40% of cases. However, identifying women with the weak D types 1, 2, and 3 phenotypes, although a much smaller subset, will also contribute to the reduced usage. Noninvasive testing of all women will also increase the sample size to reveal detection of rare RHD variants in this multiethnic population. 25 We should also take into account that although it is very important to prevent Rh alloimmunization, RhIG is in short supply and produced by immunizing volunteers with RBCs presenting a risk of infectious diseases and therefore unnecessary injections of RhIG should be avoided. Regardless of the costs, it also has been argued that it is ethically unacceptable to continue routine antiRhD prophylaxis when fetal RHD genotyping using maternal blood is available and could identify those women who do not need this product. 26 According to our results, using RHD genotyping, we could pre- Taking together our data, we can conclude that there is a diversity in RHD genotypes in this obstetric population and this knowledge can inform the risk for being alloimmunised. This can facilitate the prenatal management, as 22% were low risk and could avoid unnecessary injection of RhIG or prevent Rh alloimmunization on those patients with high risk.
